Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cyclophosphamide

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44338   clinical trials with a EudraCT protocol, of which   7368   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    790 result(s) found for: Cyclophosphamide. Displaying page 8 of 40.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2006-006395-37 Sponsor Protocol Number: BRD/06/055 Start Date*: 2007-09-06
    Sponsor Name:Joint UCLH and UCL Biomedical Research Unit
    Full Title: A randomised, multi-centre feasibility trial in AL Amyloidosis, comparing CTD with SCT in patients with low risk of Treatment Related Mortality and CTD with Mel-Dex in patients in whom SCT would no...
    Medical condition: The medical condition to be investigated is systemic AL Amyloidosis, a disorder of protein folding in which normally soluble proteins are deposited as abnormal, insoluble fibrils that progressively...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10002022 Amyloidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2016-003469-24 Sponsor Protocol Number: SPI-GCF-302 Start Date*: 2017-03-14
    Sponsor Name:Spectrum Pharmaceuticals, Inc.
    Full Title: Randomized, OpEn-Label, Active-ContrOl Trial of SPI-2012 (Eflapegrastim) Versus Pegfilgrastim in the Management of Chemotherapy-Induced Neutropenia in Early-Stage BReast Cancer Patients Receiving D...
    Medical condition: Management of Neutropenia in Patients with Breast Cancer who receiving Chemotherapy with the Docetaxel + Cyclophosphamide
    Disease: Version SOC Term Classification Code Term Level
    20.0 10005329 - Blood and lymphatic system disorders 10029354 Neutropenia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2012-003476-39 Sponsor Protocol Number: RG_12-188 Start Date*: 2012-12-04
    Sponsor Name:The University of Birmingham [...]
    1. The University of Birmingham
    2. Manchester University NHS Foundation Trust
    Full Title: Short course daily prednisolone therapy at the time of upper respiratory tract infection in children with relapsing steroid sensitive nephrotic syndrome; the PREDNOS 2 study.
    Medical condition: Relapsing steroid sensitive nephrotic syndrome
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2007-002061-12 Sponsor Protocol Number: SBG2004-1/ABCSG25/GBG53 Start Date*: 2007-08-17
    Sponsor Name:ABCSG (Austrian Breast & Colorectal Cancer Study Group)
    Full Title: PANTHER (The SBG 2004-1/ABCSG 25/GBG53 Protocol) - a randomised phase III study: Comparing two weekly and tailored epirubicin + cyclophosphamide followed by two weekly tailored docetaxel (dtEC->dtT...
    Medical condition: lymph node positive breast cancer patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: AT (Completed) FI (Prematurely Ended) DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002200-39 Sponsor Protocol Number: IBCSG54-16 Start Date*: 2017-07-05
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A randomized phase II trial of metronomic oral vinorelbine plus cyclophosphamide and capecitabine (VEX) versus weekly paclitaxel as first or second-line treatment in patients with ER-positive/HER2-...
    Medical condition: ER-positive/HER2-negative locally advanced or metastatic (stage IV)breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072737 Advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-004593-29 Sponsor Protocol Number: Uni-Koeln-1495 Start Date*: 2016-01-19
    Sponsor Name:University of Cologne
    Full Title: Phase II trial of metronomic treatment in children and adolescents with recurrent or progressive neuroblastoma
    Medical condition: recurrent or progressive high-risk Neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066595 Neuroblastoma recurrent PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2018-001075-20 Sponsor Protocol Number: IOV-2018-STS-METROPHOLYS Start Date*: 2018-05-25
    Sponsor Name:ISTITUTO ONCOLOGICO VENETO - IRCCS
    Full Title: The METROPHOLYS Study - Metronomic cyclophosphamide vs doxorubicin in elderly patients with advanced soft tissue sarcomas. Randomized, controlled open label clinical trial
    Medical condition: soft tissue sarcomas
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075333 Soft tissue sarcoma PT
    Population Age: Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2010-024067-41 Sponsor Protocol Number: COLTONE Start Date*: 2011-04-28
    Sponsor Name:F.A.R.O. FONDAZIONE PER LE ATTIVITA' DI RICERCA IN ONCOLOGIA
    Full Title: Pilot study of sequential adjuvant chemotherapy regimen including non-pegylated Liposomal Doxorubicin (MYOCET) in combination with Cyclophosphamide and Paclitaxel in elderly patients with diagnosis...
    Medical condition: Elderly patients with diagnosis of early breast Cancer candidate to adjuvant chemotherapy.
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2016-002557-38 Sponsor Protocol Number: Allo-MM-PostCy-Study Start Date*: 2018-02-13
    Sponsor Name:University Medical Center Hamburg-Eppendorf
    Full Title: Cyclophosphamide as graft-versus-host prophylaxis after allogeneic stem cell transplantation for multiple myeloma. A phase II study.
    Medical condition: Multiple myeloma
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000054086 10028228 Multiple myeloma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000806-39 Sponsor Protocol Number: CECOG/BREAST.2.2.005 Start Date*: 2005-02-10
    Sponsor Name:CECOG
    Full Title: Randomized Phase II Study of Dose-Dense Fluorouracil Plus Epirubicin75 Plus Cyclophosphamide (FEC75) and Fluorouracil Plus Epirubicin90 Plus Cyclophosphamide (FEC90) as Adjuvant Therapy for Early B...
    Medical condition: Early Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    7.0 10006199 PT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) SK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-000760-15 Sponsor Protocol Number: C-144-01 Start Date*: 2017-11-15
    Sponsor Name:Iovance Biotherapeutics, Inc.
    Full Title: A Phase 2, Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN 144) for Treatment of Patients with Metastatic Melanoma
    Medical condition: Metastatic melanoma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10027480 Metastatic malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) DE (Completed) ES (Ongoing) FR (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-022058-18 Sponsor Protocol Number: Uni-Koeln-1430 Start Date*: 2011-02-15
    Sponsor Name:University of Cologne
    Full Title: A PHASE II STUDY TO INVESTIGATE THE EFFICACY OF CYCLOPHOSPHAMIDE AS SOLE GRAFT-VERSUS-HOST-PROPHYLAXIS AFTER ALLOGENEIC STEM CELL TRANSPLANTATION (OCTET-CY)
    Medical condition: Patients with multiple myeloma, Non-Hodgkin's lymphoma or Hodgkins disease having undergone allogeneic stem cell transplantation
    Disease: Version SOC Term Classification Code Term Level
    12.1 10028566 Myeloma LLT
    12.1 10020206 Hodgkin's disease LLT
    12.1 10029547 Non-Hodgkin's lymphoma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2009-012280-34 Sponsor Protocol Number: 26866138-LYM-2034 Start Date*: 2009-12-04
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Randomized, Open-Label, Multicenter, Phase 2 Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (VR-CAP) or Rituximab, Cyclophosphamide, Doxorubicin, ...
    Medical condition: Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10012818 Diffuse large B-cell lymphoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) PT (Completed) CZ (Completed) DE (Completed) FR (Completed) ES (Completed) IT (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2008-003213-27 Sponsor Protocol Number: 26866138MMY3022 Start Date*: 2008-11-07
    Sponsor Name:ORTHO BIOTECH, Division of JANSSEN-CILAG GmbH
    Full Title: Randomized Phase III Study on Bortezomib and Low-Dose Dexamethasone with or without Continuous Low-Dose Oral Cyclophosphamide for Primary Refractory or Relapsed Multiple Myeloma
    Medical condition: Refractory or relapsed multiple myeloma after 1 to 3 previous lines of therapy, including high-dose therapy
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10028228 Multiple myeloma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-002101-62 Sponsor Protocol Number: HM13/10758 Start Date*: 2014-12-29
    Sponsor Name:University of Leeds
    Full Title: Pomalidomide in relapsed and refractory multiple myeloma (RRMM)
    Medical condition: Relapsed and Refractory Multiple Myeloma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-000796-14 Sponsor Protocol Number: HM10/9652 Start Date*: 2011-12-01
    Sponsor Name:Leeds Teaching Hospitals NHS Trust
    Full Title: Chemotherapy plus Ofatumumab at Standard or Mega dose In CLL
    Medical condition: Chronic Lymphocytic Leukaemia (CLL)
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10008958 Chronic lymphocytic leukaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2008-004263-19 Sponsor Protocol Number: WSGAM04 Start Date*: 2009-08-07
    Sponsor Name:Westdeutsche Studiengruppe GmbH
    Full Title: Randomized comparison of adjuvant Docetaxel / Cyclophosphamide with sequential adjuvant EC / Docetaxel chemotherapy in patients with HER2/neu negative early breast cancer – 6 x TC vs. 4 x EC -> 4 ...
    Medical condition: Her2/neu negative primary breast cancer, node positive disease or node negative disease with at least one other risk factor (tumor size >2cm, grade > or = 2, ER and PR negative, high uPA/PAI 1 leve...
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001866-90 Sponsor Protocol Number: AALL1131 Start Date*: 2014-07-15
    Sponsor Name:Children's Oncology Group
    Full Title: Treatment of Patients for newly diagnoised High Risk B-Lymphoblastic Leukemia (B-ALL) Testing Clofarabine in the Very High Risk Stratum
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2015-001173-41 Sponsor Protocol Number: CLO08808 Start Date*: 2015-05-18
    Sponsor Name:Genzyme Corporation
    Full Title: An Open-Label, Multi-Center Safety and Tolerability Pilot Combination Study of Clofarabine, Etoposide, Cyclophosphamide, PEG-asparaginase, and Vincristine in Pediatric Patients with Acute Lymphobla...
    Medical condition: Acute Lymphoblastic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10000845 Acute lymphoblastic leukemia LLT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2015-005594-21 Sponsor Protocol Number: ADP-04511 Start Date*: 2016-08-18
    Sponsor Name:Adaptimmune LLC
    Full Title: A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1c259T in HLA-A2+ Patients with Synovial Sarcoma
    Medical condition: Unresectable, metastatic or recurrent synovial sarcomas
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10042863 Synovial sarcoma PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 27 20:03:28 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA